Back to Stakeholders
Categories

1 domain / 2 areas / 1 specialization

QC Ventures

Data updated

Vienna, Austria

QC Ventures is the venture capital investment brand of Q·ADVISERS and describes itself as a deal-by-deal principal investor rather than a traditional fund. Its website says it has historically invested from Seed to Series A and beyond, with the ability to follow on at later stages.

QC Ventures has publicly written about psychedelic and adjacent life-science opportunities, including atai Life Sciences and COMPASS Pathways. The firm says it has backed companies with scalable business models across industries and geographies, while also highlighting its role in the psychedelics value chain from research to clinics.

The firm is associated with Vienna on its website and is tied to Q·CAPITAL VENTURES GmbH in the site footer, which points to an Austria-based operating presence. Its public materials also describe an active network of co-investors and strategic partners.

Investor Context

Venture Capital

Investment Context

This stakeholder is listed as a Venture Capital Fund within Venture Capital. Its public geography context is global. Public stage signals include Seed, Series A/B, and Growth / Late Stage. Public focus areas include Drug Development.

Public Portfolio Examples

QC Ventures presents itself as a venture arm of Q·ADVISERS that invests on a deal-by-deal basis, often alongside trusted co-investors and in ad hoc syndicates. Public materials emphasize early-stage exposure from Seed through Series A and later follow-on, with a broad, internationally oriented mandate that is not limited to one industry or geography. In the psychedelic ecosystem, QC Ventures is relevant because it has explicitly discussed investing in atai Life Sciences, referenced COMPASS Pathways through that exposure, and described itself as active across the psychedelics value chain.

Investor Type

Venture Capital Fund

Geographic Scope

Global

Psychedelic Focus

Psychedelic-Adjacent Focus

Engagement

Active

Investment Stage Focus

SeedSeries A/BGrowth / Late Stage

Investment Focus Areas

Drug Development

Investment Orientation

Engagement Status

Active

Investor Type

Venture Capital Fund

Investment Website

Recorded Investments

atai Life Sciences

Apr 30, 2020

convertible round - $24M round

QC Ventures says it supported atai from the first round and participated in subsequent financings.

ATAI Closes $24M Convertible Round

Quick Facts

HQ
Vienna, Austria
Website
Visit